Biliary Pain Persisting After Pharmacologic Therapy: Next Step in Type 3 SOD

This protocol applies to patients with type 3 sphincter of Oddi dysfunction who continue to experience biliary pain despite an adequate trial of pharmacologic treatment. Because there are no significant laboratory or imaging abnormalities in this group, establishing the diagnosis is inherently difficult — and selecting the right next step when first-line therapy has not worked is the core clinical challenge.

Clinical Scenario

Biliary pain without elevated serum aminotransferases, without common bile duct dilation, and without delayed contrast drainage. No significant laboratory or imaging abnormalities are present to explain the symptoms.

Previous Line — Goals Not Achieved

Pharmacologic treatment — including low-dose amitriptyline, duloxetine, glyceryl trinitrate, or a calcium-channel blocker (nifedipine), with ursodeoxycholic acid added when bile microlithiasis is present — did not produce adequate decrease in symptoms or resolution of biliary-type pain.

Next-Step Approach (partial view)

This protocol involves a targeted procedural intervention at the sphincter of Oddi, aimed at achieving temporary improvement in biliary pain. The clinical goal is symptom relief over a defined period. The complete protocol — including full sequencing and decision criteria — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Type 3 Biliary pain.
Diagnosis of type 3 SOD is challenging due to the lack of significant abnormalities on laboratory testing or diagnostic imaging.
The injection of botulinum toxin (Botox) into SO also causes relaxation of SO and, therefore, a temporary improvement in biliary pain after cholecystectomy for about 4 months.
At the clinical level, the injection of botulinum toxin was beneficial in 55% of patients with type 3 SOD in two uncontrolled clinical series.

DOI: 10.3390/jcm12144802

View source ↗